Literature DB >> 24907553

Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.

Jessica A Hess1, Bin Zhan2, Sandra Bonne-Année1, Jessica M Deckman1, Maria Elena Bottazzi2, Peter J Hotez2, Thomas R Klei3, Sara Lustigman4, David Abraham5.   

Abstract

Human onchocerciasis is a neglected tropical disease caused by Onchocerca volvulus and an important cause of blindness and chronic disability in the developing world. Although mass drug administration of ivermectin has had a profound effect on control of the disease, additional tools are critically needed including the need for a vaccine against onchocerciasis. The objectives of the present study were to: (i) select antigens with known vaccine pedigrees as components of a vaccine; (ii) produce the selected vaccine antigens under controlled conditions, using two expression systems and in one laboratory and (iii) evaluate their vaccine efficacy using a single immunisation protocol in mice. In addition, we tested the hypothesis that joining protective antigens as a fusion protein or in combination, into a multivalent vaccine, would improve the ability of the vaccine to induce protective immunity. Out of eight vaccine candidates tested in this study, Ov-103, Ov-RAL-2 and Ov-CPI-2M were shown to reproducibly induce protective immunity when administered individually, as fusion proteins or in combination. Although there was no increase in the level of protective immunity induced by combining the antigens into one vaccine, these antigens remain strong candidates for inclusion in a vaccine to control onchocerciasis in humans.
Copyright © 2014 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mice; Multivalent vaccine; Onchocerca volvulus; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24907553      PMCID: PMC4118642          DOI: 10.1016/j.ijpara.2014.04.006

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  55 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

Review 2.  A comprehensive, model-based review of vaccine and repeat infection trials for filariasis.

Authors:  C Paul Morris; Holly Evans; Sasha E Larsen; Edward Mitre
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  Expression, purification and characterization of low-glycosylation influenza neuraminidase in α-1,6-mannosyltransferase defective Pichia pastoris.

Authors:  Yi-Li Yang; Shao-Hong Chang; Xin Gong; Jun Wu; Bo Liu
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

4.  Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Authors:  Kathrin Kastenmüller; Diego A Espinosa; Lauren Trager; Cristina Stoyanov; Andres M Salazar; Santosh Pokalwar; Sanjay Singh; Sheetij Dutta; Christian F Ockenhouse; Fidel Zavala; Robert A Seder
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

5.  Multivalent fusion protein vaccine for lymphatic filariasis.

Authors:  Gajalakshmi Dakshinamoorthy; Abhilash Kumble Samykutty; Gnanasekar Munirathinam; Maryada Venkatarami Reddy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2012-10-02       Impact factor: 3.641

6.  VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue.

Authors:  Gustaf Christoffersson; Evelina Vågesjö; Jennifer Vandooren; Majken Lidén; Sara Massena; Rachel B Reinert; Marcela Brissova; Alvin C Powers; Ghislain Opdenakker; Mia Phillipson
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

7.  A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Authors:  James R Alaro; Andrea Partridge; Kazutoyo Miura; Ababacar Diouf; Ana M Lopez; Evelina Angov; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

8.  Single multivalent vaccination boosted by trickle larval infection confers protection against experimental lymphatic filariasis.

Authors:  S K Joseph; K Ramaswamy
Journal:  Vaccine       Date:  2013-06-02       Impact factor: 3.641

9.  Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.

Authors:  Bart W Faber; Sumera Younis; Edmond J Remarque; Roberto Rodriguez Garcia; Vanessa Riasat; Vanessa Walraven; Nicole van der Werff; Marjolein van der Eijk; David R Cavanagh; Anthony A Holder; Alan W Thomas; Clemens H M Kocken
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

10.  Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes.

Authors:  Simon A Babayan; Honglin Luo; Nick Gray; David W Taylor; Judith E Allen
Journal:  PLoS Negl Trop Dis       Date:  2012-12-27
View more
  17 in total

1.  The medical biochemistry of poverty and neglect.

Authors:  Peter J Hotez
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 2.  Onchocerca volvulus: The Road from Basic Biology to a Vaccine.

Authors:  Sara Lustigman; Benjamin L Makepeace; Thomas R Klei; Simon A Babayan; Peter Hotez; David Abraham; Maria Elena Bottazzi
Journal:  Trends Parasitol       Date:  2017-09-22

3.  Insights Into Onchocerca volvulus Population Biology Through Multilocus Immunophenotyping.

Authors:  Carmelle T Norice-Tra; José Ribeiro; Sasisekhar Bennuru; Michael P Fay; Rahul Tyagi; Makedonka Mitreva; Thomas B Nutman
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

4.  Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.

Authors:  Lisa Luu; Germanus S Bah; Ndode Herman Okah-Nnane; Catherine S Hartley; Alexandra F Glover; Tessa R Walsh; Lu-Yun Lian; Bin Zhan; Maria Elena Bottazzi; David Abraham; Nikolai Petrovsky; Nicolas Bayang; Bernard Tangwa; Rene Billingwe Ayiseh; Glory Enjong Mbah; David D Ekale; Vincent N Tanya; Sara Lustigman; Benjamin L Makepeace; John Graham-Brown
Journal:  Vaccines (Basel)       Date:  2022-05-27

5.  The Onchocerciasis Vaccine for Africa--TOVA--Initiative.

Authors:  Peter J Hotez; Maria Elena Bottazzi; Bin Zhan; Benjamin L Makepeace; Thomas R Klei; David Abraham; David W Taylor; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2015-01-29

6.  Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme.

Authors:  Hugo C Turner; Martin Walker; Sara Lustigman; David W Taylor; María-Gloria Basáñez
Journal:  PLoS Negl Trop Dis       Date:  2015-07-17

7.  Stage-Specific Transcriptome and Proteome Analyses of the Filarial Parasite Onchocerca volvulus and Its Wolbachia Endosymbiont.

Authors:  Sasisekhar Bennuru; James A Cotton; Jose M C Ribeiro; Alexandra Grote; Bhavana Harsha; Nancy Holroyd; Amruta Mhashilkar; Douglas M Molina; Arlo Z Randall; Adam D Shandling; Thomas R Unnasch; Elodie Ghedin; Matthew Berriman; Sara Lustigman; Thomas B Nutman
Journal:  mBio       Date:  2016-11-23       Impact factor: 7.867

Review 8.  The role of 'omics' in the quest to eliminate human filariasis.

Authors:  Sara Lustigman; Alexandra Grote; Elodie Ghedin
Journal:  PLoS Negl Trop Dis       Date:  2017-04-20

9.  The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice.

Authors:  Jessica A Hess; Bin Zhan; April R Torigian; John B Patton; Nikolai Petrovsky; Tingting Zhan; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  PLoS Negl Trop Dis       Date:  2016-07-07

10.  Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection.

Authors:  Sridhar Arumugam; Junfei Wei; Zhuyun Liu; David Abraham; Aaron Bell; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Sara Lustigman; Thomas R Klei
Journal:  PLoS Negl Trop Dis       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.